home-page-logo

From Concept to Clinic
to the Commercial Market.

YOUR RADIOPHARMACEUTICAL DEVELOPMENT PARTNER.

At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.

What Are Radiopharmaceuticals?

Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.

Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease.  Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario, December 3, 2019 – Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing as of today that the Company’s Board of Directors has appointed Justyna Kelly as Interim Chief Executive Officer effective immediately. Dr.  Joe McCann will stay on as an Advisor

Do you love radiopharmaceuticals as much as we do?

CPDC is always looking for exceptional people to strengthen our team.

Join Our Team

For more information contact us at: